$3.32 -$0.04 (-1.2%)

04:00 PM EDT on 04/25/19

Affimed Therapeutics (NASDAQ:AFMD)

CAPS Rating: 4 out of 5

Current Price $3.32 Mkt Cap $0.00
Open $3.34 P/E Ratio 0.00
Prev. Close $3.36 Div. (Yield) $0.00 (0.0%)
Daily Range $3.26 - $3.35 Volume 110,129
52-Wk Range $3.02 - $4.68 Avg. Daily Vol.

Caps

How do you think NASDAQ:AFMD will perform against the market?

Add Stock to CAPS Watchlist

All Players

45 Outperform
4 Underperform
 

All-Star Players

22 Outperform
3 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:AFMD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.80)
Submitted January 15, 2015

Affimed is another leap of faith stock for me, in that I made my initial trades in the stock purely on Portefeuille's instructions and currently have 1500 shares with a cost basis of 6. I finally got around to reviewing the stock today and so far I'm… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:AFMD VS S&P 500 (SPY)

Fools bearish on NASDAQ:AFMD are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about AFMD.

Recs

3
Member Avatar zzlangerhans (99.80) Submitted: 1/15/2015 1:20:17 AM : Outperform Start Price: $6.01 NASDAQ:AFMD Score: -90.97

Affimed is another leap of faith stock for me, in that I made my initial trades in the stock purely on Portefeuille's instructions and currently have 1500 shares with a cost basis of 6. I finally got around to reviewing the stock today and so far I'm pretty happy with the position. Affimed is developing bispecific antibodies, which was a very productive platform for Micromet before they were bought out by Amgen for a significant premium in 2012. Affimed's lead compound, AFM13 for relapsed/refractory Hodgkin's and CTCL, should begin a phase IIa trial in the near future.

Affimed hasn't garnered much love since their 2014 IPO, actually closing below their IPO price on the first day of trading. I can't remember the last time I saw that happen for an oncology biotech IPO. Perhaps there's something to the market's skepticism - I haven't been a very good judge of cheap bios with proprietary platforms recently. On the other hand, Affimed's base in Heidelberg makes them well-suited to be followed by Portefeuille. European-based biopharmas are often neglected by US based traders, even when they trade on US exchanges. There's clearly much more to be learned about Affimed but zzporte is already in the green thanks to a couple of timely trades so for now I'm happy to be along for the ride.

Leaderboard

Find the members with the highest scoring picks in AFMD.

Score Leader

mrtmg61

mrtmg61 (52.29) Score: +152.02

The Score Leader is the player with the highest score across all their picks in AFMD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Under5 < 20 1/9/2018 Outperform 5Y $1.28 +160.39% +6.45% +153.94 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. ak1010 99.83 2/1/2018 Outperform 5Y $1.70 +95.29% +3.85% +91.44 0 Comment
BobbyCyclone 28.58 3/10/2015 Underperform 5Y $6.06 -45.21% +42.01% +87.23 0 Comment
jeepdrew222 62.50 11/22/2017 Outperform 5Y $2.05 +61.95% +12.55% +49.40 0 Comment
shonny2 < 20 2/28/2018 Outperform 5Y $2.15 +54.42% +6.15% +48.27 0 Comment
portefeuille5 99.36 6/4/2018 Outperform 5Y $2.15 +54.42% +6.59% +47.83 0 Comment
portefeuille3 96.74 6/4/2018 Outperform 5Y $2.15 +54.42% +6.59% +47.83 0 Comment
jumbofaceplate 28.35 2/20/2018 Outperform 5Y $2.20 +50.91% +7.57% +43.34 0 Comment
cashole 99.85 9/4/2018 Underperform 1Y $5.30 -37.36% +0.96% +38.32 0 Comment
anchak 99.92 8/28/2018 Underperform NS $5.00 -33.60% +0.93% +34.53 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AFMD.

Advertisement